Stabl-Im Clinical Development Update
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Trivarx Limited has released an update on the Stabl-Im clinical development program, detailing advancements in key clinical and pre-clinical activities. The company has completed the design requirements for a clinical feasibility study and is progressing with pre-clinical studies and operational preparations. Trivarx is also in the process of selecting clinical sites and principal investigators to support the upcoming study. Additionally, discussions are ongoing with a vendor for specialized deuterium analysis necessary for the clinical study.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from TrivarX
- Notice of AGM and Closing Date for Director Nominations
- Appendix 4E - Preliminary Final Report
- June 2026 Quarterly Activities Report and Appendix 4C
- Stabl-Im clinical trial supply milestone achieved
- CRO Engaged to Advance Stabl-Im Phase 1 Trial
Later from TrivarX
- 2026 Annual Report
- Corporate Governance Statement
- Appendix 4G
- Notification of cessation of securities - TRI
- Change of Director's Interest Notice - Chris Ntoumenopoulos
Follow TrivarX into a list and get an email when it puts out news.
Follow TrivarX